Cel­gene’s up­date on its big Crohn’s drug? Trust us, we’re do­ing fine

Cel­gene in­sists that an in­ter­im analy­sis of its close­ly-watched study for GED-0301 (mon­gersen) was “en­cour­ag­ing,” but it failed to show any of its cards to­day to back that up.

Cel­gene $CELG paid a whop­ping $710 mil­lion up front to in-li­cense this drug for Crohn’s dis­ease. High­light­ed as a key pro­gram in its at­tempt to build a fran­chise for in­flam­ma­tion and im­munol­o­gy, GED-0301 is one of the com­pa­ny’s biggest ex­per­i­men­tal as­sets. And at this stage, all that Cel­gene is will­ing to say is that their in­ves­ti­ga­tors tracked an im­prove­ment in some pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER